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Abstract: Background and aim: Systemic lupus erythematosus (SLE) is associated with increased 
risk of cardiovascular disease (CVD). Among many mechanisms, accelerated atherosclerosis, 
endothelial dysfunction, and hypercoagulability play a main role. Here, we investigate whether 
inflammatory, serological and clinical markers of SLE determine and correlate with arterial 
stiffness in SLE patients. Materials and methods: Routine blood samples, inflammatory mediators, 
specific antibodies, and 24 h proteinuria were measured in 43 SLE patients and 43 age and 
sex-matched controls using routine laboratory assays. We also assessed arterial stiffness by 
measuring radial artery applanation tonometry-derived augmentation index (AI), normalized AI 
(AIx@75), aortic pulse pressure, central systolic, diastolic and peripheral blood pressure. Results: 
SLE patients showed a significantly greater arterial stiffness vs. controls, as demonstrated by the 
significantly higher AIx@75 and aortic pulse pressure. Interestingly, regression analysis showed 
that age, systolic pulse pressure, inflammatory markers (erythrocyte sedimentation rate and 
C-reactive protein), daily dose of glucocorticoids, and cumulative organ damage positively 
correlated with arterial stiffness. Conclusions: SLE patients show increased arterial stiffness which 
correlates with markers of inflammation, that is involved in early alterations in arterial walls. 
Applanation tonometry can be used to screen SLE patients for subclinical vascular damage to 
implement prevention strategies for CVD. 
Keywords: cardiovascular disease; systemic lupus erythematosus; inflammation; arterial stiffness; 
augmentation index 
 
1. Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease mainly affecting 
women of childbearing age [1]. Cardiovascular disease (CVD) is a well-known complication of SLE, 
accounting for more than one third of death causes [2,3]. Compared with age and sex-matched 
controls, SLE patients generally show an increased incidence of CVD [4], and cardiovascular events 
(CVE) account for the main cause of death [5]. The exact mechanisms contributing to the increased 
cardiovascular risk of SLE patients are still debated. Some authors highlighted the possible 
implications of systemic inflammation, specific disease-related factors, and corticosteroid therapy 
[6–9], but relatively few data are available so far. However, it is well established that patients with 
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SLE present an increased incidence of atherosclerosis and an accelerated progression of the 
atherosclerotic plaques [4,10]. SLE-related immune dysregulation and inflammatory environment 
seem to be crucial in the development of atherosclerosis. This hypothesis is further supported by the 
finding that atherogenesis-involved genes may work synergistically with autoimmune 
response-promoting genes [11]. 
Alterations in arterial distensibility and compliance have been described in chronic 
inflammatory diseases [12]. They may be due to underlying increased inflammation-mediated 
sub-clinical damage, in addition to traditional risk factors. Early in the development of 
atherosclerotic disease, some modifications of the mechanical properties of the arteries occur [13], 
and they might be considered as predictive for the risk of future CVEs. Evaluation of aortic stiffness 
by means of applanation tonometry of the radial artery is a simple and non-invasive technique for 
the quantitative assessment of subclinical vascular impairment [14]. Previous studies have 
demonstrated its prognostic utility, in addition to the other traditional techniques, for the risk 
stratification of hypertensive patients and patients with a variety of cardiovascular diseases [15,16]. 
Here, we aim at exploring whether in SLE patients the inflammatory status can be recapitulated by 
serological and inflammatory markers of disease and can translate into arterial stiffness, detectable 
with clinical and vascular alterations assessed by means of applanation tonometry of the radial 
artery. 
2. Results 
2.1. Patients’ Characteristics 
A total of 43 SLE patients (4 males and 39 females; median age 41 (11) years) were enrolled at 
the Department of Translational Medical Sciences, Federico II University, Naples, between March 
2018 and October 2018. All patients fulfilled the 2012 Systemic Lupus International Collaborating 
Clinics (SLICC) criteria [17]. Forty-three healthy subjects served as age and gender-matched 
controls. Eleven patients (25.5%) were in menopause (54.5% natural menopause and 45.5% 
iatrogenic menopause). None of the patients had metabolic syndrome. 
At the time of the enrolment, 39 patients (90.7%) were on glucocorticoid therapy (median daily 
dose of prednisone or prednisone equivalent of 7.5 (8) mg). The median duration of the disease was 
14 (18) years. SLE disease activity was assessed using the Systemic Lupus Erythematosus Disease 
Activity Index (SELENA-SLEDAI) score [18]. The median value of the disease activity index 
evaluated by SELENA/SLEDAI was 8 (10, limits 0–26). The median value of the SLICC/ACR damage 
index was 2 (2, limits 0–7). The most frequently observed clinical and laboratory components of 
SELENA-SLEDAI index were active SLE nephritis (21%), increased DNA binding (44.2%), low 
complement (48.8%), arthritis (44.1%), and rash (13.9%). 
The median value of systolic blood pressure (SBP) was 120 (20) mmHg. Blood tests included 
total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, 
homocysteine, creatinine, acid uric, glucose lymphocytes, C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), fibrinogen and lupus serology (anti-DNA antibodies, complement). 24-h 
proteinuria sample evaluated the urinary protein excretion. All the characteristics of the study 
population are shown in Table 1. 
Table 1. Characteristics of SLE (systemic lupus erythematosus) and controls subjects. 
Characteristics SLE Patients, n = 43 Controls, n = 43 p 
 Age, years 41 (11) 39.0 (12) 0.18 
 Males, n (%) 4 (9.3%) 4 (9.3%) 0.10 
 Systolic blood pressure, mmHg 120 (20) 118 (15) 0.334 
 Diastolic blood pressure, mmHg  80 (15) 8 (10)  0.225 
 Body mass index, kg/m2 23.2 (6.0) 23.0 (6) 0.720 
 Hypertension, n (%) 7 (16.3%) 6 (13.9%) 0.422 
 Type 2 diabetes mellitus, n (%) 1 (2.5%) 0  0.225 
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 Smoking habit, n (%) 21 (48.8%) 18 (41.9%) 0.633 
Disease duration, years 14.0 (18)   
Duration of steroid therapy, years 10 (13)   
Mean daily dose of prednisone, mg 7.5 (8)   
Diagnosis of nephritis, n (%) 9 (22.5%)   
Mean SLEDAI score 8.0 (10)   
Mean SDI score 2 (2)   
ANA 37 (86%)   
anti-dsDNA 19 (44.2%)   
ENA 25 (58.1%)   
Low complement levels (C3 or C4) 21 (48.8%)   
Total cholesterol, mg/dL 174 (75)   
 LDL cholesterol, mg/dL 112 (53)   
 HDL cholesterol, mg/dL 52 (17)   
 Homocysteine, µmol/dL  14 (7)   
 Creatinine, mg/dL 0.7 (0.2)   
 Estimated GFR, mL/min/1.73 m2 109 (23.5)   
 Proteinuria, mg/day 345 (90)    
 Uric acid, mg/dL 4.8 (1.5)   
 Glucose, mg/dL 77 (7)   
 Lymphocytes, n/µL 1800 (1000)   
  C-reactive protein, mg/L 0.33 (0.48)   
  Erythrocyte sedimentation rate, mm/h 18 (25)   
  Fibrinogen, mg/dL 282 (85)   
Data are expressed as median (interquartile range), absolute number, or percentages as appropriate. 
List of abbreviations: SLE, systemic lupus erythematosus; LDL, low-density lipoproteins; HDL, 
high-density lipoproteins; GFR, glomerular filtration rate; SLEDAI, Systemic Lupus Erythematosus 
Disease Activity Index; SDI, Systemic Lupus International Collaborating Clinics/American College 
of Rheumatology Damage Index; ANA, Antinuclear antibody positivity; anti-dsDNA, Anti-double 
stranded DNA; ENA, Extractable Nuclear Antigens. 
2.2. Comparison of Arterial Stiffness between Systemic Lupus Erythematosus (SLE) and Healthy Controls 
SLE patients exhibited increased arterial stiffness compared to controls (Figure 1, Panels A,C). 
In particular, aortic pulse pressure (AoPP) was higher in SLE patients compared to controls (29.0 
(17) mmHg vs. 27 (10) mmHg; p = 0.03). SLE patients presented significantly higher values of AIx@75 
(21.0 (17) vs. 9.0 (16); p < 0.001) (Figure 1, Panels B,C). AIx was also higher in patients than in 
controls, even though the difference was not statistically different. 
Reprodicibility of AoPP, AIx, and AIx@75 was excellent (intraclass coefficient correlations of 
0.997, 0.981, and 0.989 for the intra-observer variability, and of 0.980, 0.939, and 0.970 for the 
inter-observer variability, respectively). 
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Figure 1. (A) Box plots of aortic pulse pressure (AoPP) in SLE patients and controls. SLE patients 
showed increased arterial stiffness compared to controls. AoPP resulted higher in SLE patients 
compared to controls (* p = 0.03). (B) Box plots of AIx@75 in SLE patients and controls. Higher values 
of AIx@75 (* p < 0.001) were detected in SLE patients. (C) Values of arterial stiffness in SLE patients 
and controls. List of abbreviations: SLE, Systemic Lupus Erythematosus. Outliers are shown as blank 
dots. The horizontal dotted line delimits zero. 
2.3. Predictors of Arterial Stiffness 
In the univariate analysis (Table 2), AoPP correlated with age (r = 0.4; p < 0.05), SBP (r = 0.66; p < 
0.001), CRP levels (r = 0.37; p < 0.05), ESR (r = 0.34; p = 0.05), daily dose of prednisone (r = 0.33; p = 
0.05) and damage index (r = 0.30; p = 0.05). Moreover, patients who displayed organ damage, defined 
by a SLICC/ACR damage index score (SDI) ≥ 1, had significantly higher AoPP than those with a SDI 
= 0 (32 (9) vs. 28 (7), p = 0.03), as shown in Figure 2. 
Table 2. Correlation between markers of arterial stiffness and clinical and laboratory parameters in 
SLE subjects. 
Clinical and Laboratory Parameters Linear Correlation Coefficient (r) 95% C.I. p 
Univariate Analysis for AoPP 
  Age 0.40 
0.21 to 
0.62 0.02 
  Systolic blood pressure 0.66 
0.44 to 
0.80 < 0.001 
  C-reactive protein 0.37 
0.07 to 
0.61 0.03 
  Erythrosedimentation rate 0.34 
0.10 to 
0.53 0.05 
  Daily dose of prednisone 0.33 0.15 to 
0.53 
0.05 
  SDI score 0.30 0.12 to 
0.44 
0.05 
Univariate Analysis for AIx@75 
  Age 0.57 0.19 to 
0.82 
< 0.001 
  Lymphocytes −0.44 −0.50 to < 0.001 
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−0.12 
Univariate Analysis for AIx 
  Age 0.59 
0.21 to 
0.85 
< 0.001 
  Lymphocytes −0.34 −0.55 to −0.15 0.05 
  Creatinine −0.37 −0.62 to −0.12 0.04 
List of abbreviations: SLE, Systemic Lupus Erythtematosus; C.I., confidence interval; AoPP, aortic 
pulse pressure; AIx, augmentation index; AIx@75, normalized to a 75 bpm heart rate AIx; SDI, 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage 
Index. 
 
Figure 2. Box plots of AoPP in SLE patients with and without organ damage. Patients with organ 
damage, defined by a SDI score ≥ 1, showed significantly higher values of AoPP than those without 
no organ damage (32 (9) vs. 28 (7), * p = 0.03). List of abbreviations: SLE, systemic lupus 
erythematosus; SDI, Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index. 
AIx@75 showed positive correlation with age (r = 0.57; p < 0.001), negative correlation with 
lymphocyte count (r = −0.44; p < 0.01). AIx directly correlated with age (r = 0.59; p < 0.001), inversely 
blood creatinine levels (r = −0.37; p < 0.05) and lymphocyte count (r = −0.34; p = 0.05). 
Regarding the clinical manifestations, both AIx@75 and AIx resulted significantly higher in 
patients with clinical manifestations, especially in patients who had mucosal ulcers (p = 0.03 and 
0.04, respectively) and active nephritis (p = 0.01 and p = 0.006) at the time of the study. 
At the multiregression analysis (Table 3), AoPP correlated with age (r2 = 0.53; 95% confidence 
interval (C.I.) 0.20 to 0.89; p = 0.01), SBP (r2 = 0.29; 95% C.I. 0.12 to 0.45; p = 0.001), ESR (r2 = 0.29; 95% 
C.I. 0.09 to −0.49; p = 0.005). Both AIx@75 and AIx correlated with age (r2 = 0.80 with 95% C.I. 0.33 to 
1.28 and p < 0.001 for AIx@75; r2 = 0.95 with 95% C.I. 0.48 to 1.43 and p < 0.001 for AIx). 
Table 3. Multiregression analysis between markers of arterial stiffness and clinical and laboratory 
parameters in SLE subjects. 
Clinical and Laboratory Parameters Coefficient of Determination (r2) 95 % C.I. p 
Multiregression Analysis for AoPP 
  Age 0.53 0.20 to 0.89 0.01 
  Systolic blood pressure 0.29 0.12 to 0.45 0.001 
  Erythrosedimentation rate 0.29 0.09 to -0.49 0.005 
Multiregression Analysis for AIx@75 
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  Age 0.80 0.33 to 1.28 < 0.001 
Multiregression Analysis for AIx 
  Age 0.95 0.48 to 1.43 < 0.001 
List of abbreviations: SLE, Systemic Lupus Erythtematosus; C.I., confidence interval; AoPP, aortic 
pulse pressure; AIx, augmentation index; AIx@75, normalized to a 75 bpm heart rate AIx. 
3. Discussion 
CVD is an important factor for SLE mortality [7]. Importantly, SLE pathophysiology is 
characterized by increased incidence of atherosclerosis with accelerated progression of 
atherosclerotic plaques [4,10]. Hence, early prediction of CVD is very important for appropriate 
treatment and follow-up of SLE patients. 
Previous work assessing arterial stiffness in SLE patients by means of applanation tonometry 
provided controversial results [19–25]. In our study we found significantly higher values of AIx@75 
and AoPP at applanation tonometry in SLE patients compared to age and sex-matched healthy 
controls. Furthermore, AoPP showed a significant correlation with inflammatory markers such as 
ESR. In SLE, immune dysregulation and the inflammatory environment seem to be crucial in the 
development of atherosclerosis. CRP levels are known to be independent predictors of 
cardiovascular risk, and contribute directly to the genesis of atherosclerotic lesions [26], determining 
endothelial dysfunction [27], which is a marker of vascular damage and is a well-known feature of 
SLE [28]. Endothelial dysfunction is a main factor in the early development of atherosclerosis in SLE 
patients [29]. This is considered as a negative prognostic factor for CVD, possibly related to a specific 
dyslipidaemic pattern in SLE patients [30] and to the increase of inflammatory cytokines, especially 
type I interferons (IFNs) [31,32]. Indeed, hypercholesterolemia has been described as the main 
predictor of cardiovascular events (CVE) in SLE patients [33,34]. In particular, LDL-cholesterol levels 
have been demonstrated to be associated with impairment in the augmentation index [35]. 
Nevertheless, in line with previous studies [21,36] we found no correlation between cholesterol 
levels and AoPP. This result should be interpreted considering that none of the patients had 
hypercholesterolemia, defined as serum total cholesterol higher than 250 mg/dL, the threshold 
correlated with a significant increase of cardiovascular risk [7]. 
Among other traditional cardiovascular risk factors, age showed the strongest correlation with 
all the parameters of arterial stiffness. This is coherent with what is known in the general population, 
as arterial stiffness increases with age [37,38]. AoPP also showed a significant positive correlation 
with SBP (Table 2). These findings confirm data previously reported, as a strong association between 
hypertension and arterial stiffness in general population has been described [39,40]. Interestingly, in 
our study, SBP correlated with arterial stiffness even in normotensive patients. 
On the other hand, arterial stiffness did not show a significant correlation with disease activity, 
assessed with the SELENA-SLEDAI 2K tool. However, the parameters of arterial stiffness were 
significantly higher in patients with mucosal ulcers and active nephritis. Interestingly, an association 
between subclinical atherosclerosis and impaired renal function has been reported in some studies 
on SLE patients [41,42]. 
One of the most debated SLE-related factors contributing to vascular stiffness is represented by 
glucocorticoid therapy. In our analysis, AoPP showed a significant correlation with the dose of 
prednisone (or equivalent). The contribution of glucocorticoids to the CV risk in SLE patients is yet 
to be determined, but it has to be acknowledged that patients treated with higher glucocorticoids 
disease are usually those with the most severe clinical phenotype. Indeed, our results show that 
arterial stiffness correlates with cumulative organ damage, as assessed by the SLICC/ACR damage 
index (SDI). AoPP was significantly higher in patients with (SDI score ≥ 1) than in those with no 
organ damage (Figure 2). Moreover, aortic pulse pressure had a positive correlation with the extent 
of organ damage, as measured by the damage index, in agreement with previous studies [43]. These 
findings should be further explored to determine whether arterial stiffness might act as a predictor 
of organ damage in SLE patients. 
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The impact of glucocorticoid therapy on cardiovascular risk is relevant also because of the 
metabolic alterations occurring with long-term treatment with steroids [33,44]. However, it has been 
reported that such alterations only occur with daily doses exceeding 10 mg and for therapies lasting 
more than 6 months [45]. Moreover, since inflammation is strongly correlated with the 
atherosclerotic process, low-dose corticosteroids might have a beneficial anti-inflammatory and 
anti-atherosclerotic action. For these reasons, corticosteroids remain beneficial treatment in SLE, but 
dose-tapering should be started as soon as possible, depending on the clinical status of the patient. 
Glucocorticoid tapering should be encouraged as soon as disease activity allows it, preferring 
combination therapy [46]. Yet, our study highlights that some therapy related-risk may exist. 
4. Materials and Methods 
4.1. Study Design and Ethics Statement 
In our study we included 43 subjects older than 18 years who fulfilled the 2012 Systemic Lupus 
International Collaborating Clinics (SLICC) criteria [17], treated, at enrolment, with prednisone at a 
stable dose for at least 3 months. Exclusion criteria were: pregnancy, history of cardiovascular events 
or known coronary disease, uncontrolled hypertension, the presence of arrhythmias or the presence 
of a pacemaker, cancer or acute infectious diseases. A full clinical history and physical examination, 
including weight, height, body mass index, smoking status and blood pressure, was collected. The 
mean disease duration, demographics, and clinical data were obtained from the medical records. 
Forty-three healthy subjects served as age and gender-matched controls. 
The study was conducted in accordance with the principles of the 1975 Declaration of Helsinki 
and good clinical practice guidelines of the International Conference of Harmonization (ICH GCP). 
Informed consent was obtained from all patients before the procedure, and the study was approved 
by the local ethical committee of the University of Naples Federico II “Carlo Romano” (348/2018 
approved 14/03/2018). 
4.2. Clinical and Laboratory Data 
Routine blood samples, inflammatory mediators, specific antibodies, and 24 h proteinuria were 
measured using routine laboratory assays. A detailed clinical history was collected, including 
current and cumulative use of glucocorticoids. Disease activity in the preceding 30 days was 
assessed with the use of the SELENA-Systemic Lupus Erythematosus Disease Activity Index 
(SELENA-SLEDAI-2K) [18]. Cumulative organ damage was calculated with the Systemic Lupus 
International Collaborating Clinic/American College of Rheumatology (SLICC/ACR) damage index 
(Table 1) [17]. 
4.3. Vascular Assessment 
Brachial blood pressure was measured at the non-dominant arm with a sphygmomanometer. 
Parameters of arterial stiffness were derived by a high fidelity applanation tonometer (SphygmoCor 
device, AtCor Medical, Sydney, Australia). Measurements were performed in a quiet and controlled 
temperature room, after 10 min in supine position, with the patient fasting and refraining from 
alcohol and coffee assumption for at least 10 h. All measurements were made in duplicate by two 
trained operators (D.C., P.P.) according to the international recommendations (the values with the 
higher Operator Index were used in the analysis) and interpreted by a different operator (V.M.) who 
was blind to the clinical characteristics of the patients. Aortic pulse pressure (AoPP), Augmentation 
Index (AIx) and Augmentation Index normalized to heart rate of 75 bpm (AIx@75) were the 
parameters considered in order to evaluate arterial stiffness. In particular, AoPP was defined as the 
difference between the first peak of systolic blood pressure and the diastolic blood pressure; AIx was 
calculated as the ratio of late systolic pressure to early systolic pressure, expressed as a percentage of 
the sphygmic wave [47]. 
4.4. Statistical Analyses 
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Continuous variables were expressed as median ± interquartile range; categorical variables 
were expressed as frequencies or percentages. The comparison between patients’ and controls’ data 
was performed by non-parametric Mann–Whitney U-test for independent samples. Factors 
associated with arterial stiffness, in SLE patients, were analyzed by the use of Pearson’s correlation 
coefficient or Spearman’s correlation (univariate analysis) and multiple linear regression with OLS 
method (multivariate analysis). Variables correlated to stiffness with a p-value below 10% in 
univariate analysis were considered for the multivariate model. A p value ≤0.05 was considered as 
statistically significant. 
Intra- and inter-observer variabilities for parameters of arterial stiffness were evaluated by 
means of intraclass correlation coefficients (10 random exams were preformed twice by an operator 
and compared with the results obtained by a second operator). 
5. Conclusions 
Overall, our results support the concept that inflammation is a main determinant of 
cardiovascular complications in SLE. As highlighted by a recent meta-analysis, SLE patients have a 
higher carotid intima-media thickness and an increased prevalence of carotid plaques, supporting 
the evidence for an increased CVD risk [9]. 
Our study has some limitations to be considered. The sample size is small and may lack 
statistical power to define additional factors correlated to arterial stiffness, especially concerning the 
results of the regression analysis. Moreover, a cause–effect relation cannot be inferred from a 
cross-sectional study. Nevertheless, our results suggest that a regular and careful serological and 
clinical assessment together with vascular investigations is useful to identify an early impairment of 
arterial stiffness in patients with SLE. Our data also support the use of non-invasive techniques such 
as applanation tonometry of the radial artery to assess the accelerated progression of atherosclerotic 
damage of the vessel wall in SLE patients. It is particularly important to stratify high-risk patients in 
order to plan an appropriate therapeutic approach for SLE patients and control traditional risk 
factors to avoid subclinical vascular impairment evolving into manifest cardiovascular events [48]. 
Therefore, early detection of increased aortic stiffness in these patients may be beneficial to highlight 
the vascular damage and to prompt an early therapeutic intervention. Eventually, this approach 
may attenuate the inflammatory process and prevent cardiovascular damage. 
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